These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38070482)

  • 21. [Cost of systemic lupus erythematosus for adult patients with active and treated disease in France (LUCIE study)].
    Amoura Z; Deligny C; Pennaforte JL; Hamidou M; Blanco P; Hachulla E; Pourrat J; Queyrel V; Garofano A; Maurel F; Levy-Bachelot L; Boucot I
    Rev Med Interne; 2014 Nov; 35(11):700-8. PubMed ID: 24630588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
    Jiang M; Near AM; Desta B; Wang X; Hammond ER
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.
    Clarke AE; Yazdany J; Kabadi SM; Durden E; Winer I; Griffing K; Costenbader KH
    Semin Arthritis Rheum; 2020 Aug; 50(4):759-768. PubMed ID: 32531505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-care utilization and costs in adults with systemic lupus erythematosus in the United Kingdom: a real-world observational retrospective cohort analysis.
    Samnaliev M; Barut V; Weir S; Langham J; Langham S; Wang X; Desta B; Hammond E
    Rheumatol Adv Pract; 2021; 5(3):rkab071. PubMed ID: 34622127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy.
    Doria A; Iaccarino L; La Montagna G; Mathieu A; Piga M; Galeazzi M; Iuliano A; Maurel FB; Garofano AM; Perna AG; Porcasi RE
    Clin Exp Rheumatol; 2015; 33(3):375-84. PubMed ID: 26005879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender Disparities in Hospitalization Outcomes and Healthcare Utilization Among Patients with Systemic Lupus Erythematosus in the United States.
    Uwumiro F; Okpujie VO; Osemwota O; Okafor NE; Otu MI; Borowa A; Ezerioha P; Tejere E; Alemenzohu H; Bojerenu MM
    Cureus; 2023 Jul; 15(7):e41254. PubMed ID: 37529818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs of illness and quality of life in patients with systemic lupus erythematosus in South Korea.
    Cho JH; Chang SH; Shin NH; Choi BY; Oh HJ; Yoon MJ; Lee EY; Lee EB; Lee TJ; Song YW
    Lupus; 2014 Aug; 23(9):949-57. PubMed ID: 24563501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study.
    Joo YB; Sung YK; Shim JS; Kim JH; Lee EK; Lee HS; Bae SC
    Rheumatol Int; 2015 May; 35(5):879-86. PubMed ID: 25300729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis.
    Carls G; Li T; Panopalis P; Wang S; Mell AG; Gibson TB; Goetzel RZ
    J Occup Environ Med; 2009 Jan; 51(1):66-79. PubMed ID: 19136875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
    Bell CF; Ajmera MR; Meyers J
    Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UK.
    Stirnadel-Farrant HA; Golam SM; Naisbett-Groet B; Gibson D; Langham J; Langham S; Samnaliev M
    Rheumatol Ther; 2023 Oct; 10(5):1183-1197. PubMed ID: 37400683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus.
    Yeo AL; Koelmeyer R; Kandane-Rathnayake R; Golder V; Hoi A; Huq M; Hammond E; Nab H; Nikpour M; Morand EF
    Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs associated with severe and nonsevere systemic lupus erythematosus in Canada.
    Clarke AE; Urowitz MB; Monga N; Hanly JG
    Arthritis Care Res (Hoboken); 2015 Mar; 67(3):431-6. PubMed ID: 25185936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: the LUCIE Study.
    Cervera R; Rúa-Figueroa I; Gil-Aguado A; Sabio JM; Pallarés L; Hernández-Pastor LJ; Iglesias M
    Rev Clin Esp (Barc); 2013 Apr; 213(3):127-37. PubMed ID: 23398815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population.
    Furst DE; Clarke A; Fernandes AW; Bancroft T; Gajria K; Greth W; Iorga SR
    J Med Econ; 2013; 16(4):500-9. PubMed ID: 23363329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of end-stage renal disease in systemic lupus erythematosus patients: a nationwide population-based study.
    Yu KH; Kuo CF; Chou IJ; Chiou MJ; See LC
    Int J Rheum Dis; 2016 Nov; 19(11):1175-1182. PubMed ID: 26864331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The risk of end-stage renal disease in systemic lupus erythematosus: A nationwide population-based study in Korea.
    Choi HS; Han KD; Jung JH; Kim CS; Bae EH; Ma SK; Kim SW
    Medicine (Baltimore); 2019 Jul; 98(28):e16420. PubMed ID: 31305460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.